Anti–CTLA-4 therapy requires an Fc domain for efficacy

@inproceedings{Ingram2018AntiCTLA4TR,
  title={Anti–CTLA-4 therapy requires an Fc domain for efficacy},
  author={Jessica R Ingram and Olga S. Blomberg and Mohammad Rashidian and Lestat Ali and Scott J. Garforth and Elena Fedorov and Alexander A. Fedorov and Jeffrey B. Bonanno and Camille Le Gall and Stephanie Crowley and Camilo Espinosa and Tamara Biary and Edmund J. Keliher and Ralph Weissleder and Steven C. Almo and Stephanie K Dougan and Hidde L. Ploegh and Michael Dougan},
  booktitle={Proceedings of the National Academy of Sciences of the United States of America},
  year={2018}
}
Ipilimumab, a monoclonal antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved "checkpoint"-blocking anticancer therapy. In mouse tumor models, the response to antibodies against CTLA-4 depends entirely on expression of the Fcγ receptor (FcγR), which may facilitate antibody-dependent cellular phagocytosis, but the… CONTINUE READING